DSM’s strategic partner, Brains Bioceutical – a pioneer in the cannabinoid space and a global leader in the manufacture of natural-origin cannabinoid API solutions – has recently announced the opening of a state-of-the-art 21,000 sq/ft cannabinoid manufacturing facility in Sandwich, Kent, UK. Together with BSPG Laboratories – a wholly owned subsidiary of Brains Bioceutical – this new site is set to become the global center for cannabinoid research, testing and commercial production commercial production of natural EU GMP APIs.
Senior Director of Pharma and Medical Nutrition at DSM, Kelsey Achenbach, spoke on the facility opening, “We are delighted to be working in partnership with Brains Bioceutical to enhance our access to cannabinoid research and production capabilities and ultimately continue to expand our API portfolio. Research in cannabinoids is increasing rapidly and their potential in therapeutic areas, such as CNS diseases and mental health treatment, is very exciting. As a purpose-led partner in early-stage drug development, DSM has the core competencies – and now extended state-of-the-art research facilities – to support pharmaceutical companies in entering the cannabinoid market with science-backed pharmaceuticals.”
The new facility expansion provides the crucial infrastructure required for Brains Bioceutical and BSPG Laboratories to become one of the world’s leading cannabinoid API manufacturers. BSPG is one of very few companies supported by the appropriate GMP certification for both human and veterinary use and is registered with the MHRA, the UK authorities, as an API manufacturer for cannabinoids. The team working at the center will focus on furthering preclinical research and clinical trials to provide greater evidence to support the efficacy and safety of cannabinoids on a global scale.
In partnership with Brains Bioceutical, DSM can provide customers with access to the purest THC-free cannabidiol (CBD) API available on the market today. At DSM, we continue to advance research into various pioneering technologies to – for example – create a comprehensive formulation toolkit that effectively improves CBD bioavailability, while addressing different market needs and supporting better patient outcomes. In partnership with Brains Bioceutical, we are also exploring the therapeutic potential of a number of other cannabinoid APIs in addition to CBD, including some rare cannabinoid molecules.
Discover more on how DSM is opening new frontiers for cannabinoid innovation here.